

Eran Nizri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1406155/publications.pdf>

Version: 2024-02-01

43
papers

1,102
citations

516561

16
h-index

395590

33
g-index

43
all docs

43
docs citations

43
times ranked

1784
citing authors

#	ARTICLE	IF	CITATIONS
1	The Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2022, 32, 1617-1623.	1.1	13
2	Gastric Cancer-Derived Extracellular Vesicles (EVs) Promote Angiogenesis via Angiopoietin-2. Cancers, 2022, 14, 2953.	1.7	6
3	Severe Postoperative Complications are Associated with Impaired Survival in Primary but not in Recurrent Retroperitoneal Sarcoma. Annals of Surgical Oncology, 2021, 28, 2693-2699.	0.7	6
4	Classification of node-positive melanomas into prognostic subgroups using keratin, immune, and melanogenesis expression patterns. Oncogene, 2021, 40, 1792-1805.	2.6	12
5	Skin exposure to UVB light induces a skin-brain-gonad axis and sexual behavior. Cell Reports, 2021, 36, 109579.	2.9	19
6	Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence. Annals of Surgical Oncology, 2021, , 1.	0.7	3
7	ASO Visual Abstract: Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence. Annals of Surgical Oncology, 2021, , 1.	0.7	1
8	Innate inflammatory markers for predicting survival in retroperitoneal sarcoma. Journal of Surgical Oncology, 2020, 122, 1655-1661.	0.8	4
9	Protective Desmoplasia in Pancreatic Adenocarcinoma: High Vitamin D Receptor Expression and Collagen Content. Anticancer Research, 2020, 40, 6457-6464.	0.5	2
10	Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients – A propensity score analysis. Journal of Surgical Oncology, 2019, 119, 318-323.	0.8	9
11	Size and lipid modification determine liposomal Indocyanine green performance for tumor imaging in a model of rectal cancer. Scientific Reports, 2019, 9, 8566.	1.6	7
12	Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience. European Journal of Surgical Oncology, 2019, 45, 2103-2108.	0.5	10
13	European association for endoscopic surgery (EAES) consensus statement on single-incision endoscopic surgery. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 996-1019.	1.3	51
14	Desmoplasia in Lymph Node Metastasis of Pancreatic Adenocarcinoma Reveals Activation of Cancer-Associated Fibroblasts Pattern and T-helper 2 Immune Cell Infiltration. Pancreas, 2019, 48, 367-373.	0.5	16
15	Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. European Journal of Surgical Oncology, 2019, 45, 371-375.	0.5	13
16	Treatment of Peritoneal Surface Malignancies with Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC): Experience in Israel. Indian Journal of Surgical Oncology, 2019, 10, 19-23.	0.3	1
17	MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. Oncotarget, 2019, 10, 2644-2656.	0.8	11
18	Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. European Journal of Surgical Oncology, 2018, 44, 1100-1104.	0.5	24

#	ARTICLE	IF	CITATIONS
19	T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 475-481.	0.7	11
20	Optimization of liposomal indocyanine green for imaging of the urinary pathways and a proof of concept in a pig model. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 963-970.	1.3	12
21	Blood Transfusion in Cytoreductive Surgery: Better Not at All. <i>Annals of Surgical Oncology</i> , 2018, 25, 711-712.	0.7	0
22	ASO Author Reflections: Even in Pancreatic Cancer, not all N Diseases are Created Equal. <i>Annals of Surgical Oncology</i> , 2018, 25, 804-805.	0.7	0
23	Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 507-517.	0.6	27
24	Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC. <i>Annals of Surgical Oncology</i> , 2018, 25, 3264-3270.	0.7	20
25	2018 ESMO Sarcoma and GIST Symposium: "take-home messages"™ in soft tissue sarcoma. <i>ESMO Open</i> , 2018, 3, e000390.	2.0	6
26	Intraoperative Localization of Rectal Tumors Using Liposomal Indocyanine Green. <i>Surgical Innovation</i> , 2017, 24, 139-144.	0.4	7
27	Role of the $\alpha 7$ Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2017, 17, 90-99.	0.5	30
28	Adipose-Induced Retroperitoneal Soft Tissue Sarcoma Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells. <i>Molecular Cancer Research</i> , 2016, 14, 1254-1265.	1.5	6
29	Analysis of histological and immunological parameters of metastatic lymph nodes from colon cancer patients reveals that T-helper 1 type immune response is associated with improved overall survival. <i>Medicine (United States)</i> , 2016, 95, e5340.	0.4	11
30	Imaging the urinary pathways in mice by liposomal indocyanine green. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1057-1064.	1.7	23
31	Optimal management of sarcomas of the breast: an update. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 705-710.	1.1	14
32	Epithelial-to-Mesenchymal Transition (EMT) in Intraductal Papillary Mucinous Neoplasm (IPMN) is Associated with High Tumor Grade and Adverse Outcomes. <i>Annals of Surgical Oncology</i> , 2014, 21, 750-757.	0.7	27
33	Modulation of inflammatory pathways by the immune cholinergic system. <i>Amino Acids</i> , 2013, 45, 73-85.	1.2	55
34	Acetylcholine and Cholinergic Modulation of Immune Responses. , 2012, , 97-120.		0
35	Current management practice of breast borderline lesions"need for further research and guidelines. <i>American Journal of Surgery</i> , 2012, 203, 721-725.	0.9	22
36	Activation of the Cholinergic Anti-Inflammatory System by Nicotine Attenuates Neuroinflammation via Suppression of Th1 and Th17 Responses. <i>Journal of Immunology</i> , 2009, 183, 6681-6688.	0.4	244

#	ARTICLE	IF	CITATIONS
37	Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 121-127.	1.1	36
38	Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. <i>Journal of Neuroimmunology</i> , 2008, 203, 12-22.	1.1	103
39	Novel Approaches to Treatment of Autoimmune Neuroinflammation and Lessons for Drug Development. <i>Pharmacology</i> , 2007, 79, 42-49.	0.9	12
40	IBU-Octyl-Cytisine, a novel bifunctional compound eliciting anti-inflammatory and cholinergic activity, ameliorates CNS inflammation by inhibition of T-cell activity. <i>International Immunopharmacology</i> , 2007, 7, 1129-1139.	1.7	12
41	The Role of Cholinergic Balance Perturbation in Neurological Diseases. <i>Drug News and Perspectives</i> , 2007, 20, 421.	1.9	16
42	Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. <i>Neuropharmacology</i> , 2006, 50, 540-547.	2.0	179
43	Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments. <i>Neuroscience Letters</i> , 2005, 376, 46-50.	1.0	21